METIS
Live / Applied — Statement of use — processing complete, to examiner (as of 23 Dec 2025)
What this means for you
Not registered yet, but its 25 Jun 2021 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90795166
- Mark type
- Stylized text
- Filed
- 25 Jun 2021
- Published for opposition
- 22 Nov 2022
- Attorney of record
- Douglas R. Wolf
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations for target delivery of small molecules, RNA and gene therapies for central nervous system diseases, liver diseases, lung diseases, cancer, immune system diseases, rare diseases caused by genetic anomalies, kidney diseases, gastrointestinal diseases, and infectious diseases; drug delivery agents in the form of lipid nanoparticles, and sustained and controlled release formulations that facilitate the delivery of pharmaceutical preparations and improve the patients' medication experience
- Class 042 — Scientific and technological services: pharmaceutical research and development services
Owner
- METIS THERAPEUTICS INC., CAMBRIDGE, MA, US
- METIS THERAPEUTICS INC., CAMBRIDGE, MA, US
- Metis Pharmaceuticals US Inc., Cambridge, MA, US
Prosecution history
- 23 Dec 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 22 Dec 2025 — USE AMENDMENT FILED
- 22 Dec 2025 — TEAS STATEMENT OF USE RECEIVED
- 12 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Dec 2025 — SOU EXTENSION 5 GRANTED
- 06 Jul 2025 — SOU EXTENSION 5 FILED
- 12 Dec 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 07 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 22 Nov 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Nov 2024 — SOU EXTENSION 4 GRANTED
- 22 Nov 2024 — SOU EXTENSION 4 FILED
- 22 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 11 Jul 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Jul 2024 — SOU EXTENSION 3 GRANTED
- 11 Jul 2024 — SOU EXTENSION 3 FILED